FDA approves three treatments for diabetes

Share this article:
FDA approves three treatments for diabetes
FDA approves three treatments for diabetes

Takeda announced that the FDA has approved Nesina (alogliptin), Oseni (alogliptin and Pioglitazone), and Kazano (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise. Federal approval was based on worldwide placebo- and active-controlled clinical trials of Nesina involving more than 13,000 patients.

Nesina is a dipeptidyl peptidase-4 inhibitor (DPP-4i) that slows the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). Oseni, which combines alogliptin with pioglitazone, is the first to include both a DPP-4i and a thiazolidinedione (TZD) in a single tablet. Kazano combines alogliptin with metformin HCl, a biguanide also indicated for the treatment of diabetes.

Share this article:

More in Products

LINK Innovation Competition crowns Walalight best

The Walalight™ system, which simulates natural sunlight exposure and promotes regular circadian rhythms, won first place at the 2014 LINK Innovation Competition on Monday in Chicago.

Nestlé Professional MINOR adds low-sodium, gluten-free base

Nestlé Professional MINOR adds low-sodium, gluten-free base

MINOR's Low Sodium Gluten Free Base is available in chicken, beef and vegetable, Nestle Professional announced.

Larson Electronics debuts mobile power distribution system

Larson Electronics debuts mobile power distribution system

The Larson Electronics MDC-240-100MB-8X120 temporary power distribution system is now available for those who need to use power sources independently of a work area.